Attovia Therapeutics Inc.

ATTO | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.30

-$0.84 (-3.79%)

At close: Sep 21, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.79%

(1D)

Rating

Updated: Aug 17, 2026

18.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $916.54M

1D Range

20.21 22.42

52W Range

16.15 28

Valuation (TTM)

PE -22.90

PB 8.13

EV/EBITDA -19.52

Valuation (NTM)

Forward PE N/A

Forward PEG 0.58

Price Target $45.33

Cash Flow

FCF Yield -3.9%

SBC Adj. FCF Yield -3.9%

SBC Impact N/A

Margins

Gross Margin -8.4%

Operating Margin -9279.6%

FCF Margin -7842.9%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -30.6%

ROE -32.0%

ROIC -35.5%

Financial Health

Net Cash

$113.09M

Current Ratio 9.39

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-3...

Sector Healthcare

Industry Biotechnology

Employees 44

IPO Date Aug 4, 2026

Website www.attovia.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.